Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)

Inclusion Criteria: * Subjects examined at ambulatory medicine medicine center CHUV / PMU and for wich serum sample is required for the research of specific IgE (allergic patients, allergic group) or for any other reason (immunological) (non-allergic control patients, control group) * Subjects for which it is expected (allergic group subjects) or who will be asked (non-allergic control group) to perform a panel of standard prick tests as basic allergological investigation, including pollen birch, grasses, mites (D pter, D far), cat dander. * Obtain informed consent from each subject before any study procedure. Exclusion Criteria: * Presence of positive HIV-1 viremia by the ultra-sensitive method in the 12 months preceding the study. * Use of any investigational or non-registered product (drug or vaccine) * Chronic administration (more than 14 days) of immunosuppressive or immunomodulatory drugs in the 6 months preceding the study for corticosteroids. This means a dose of Prednisone or equivalent substance greater than or equal to 0.5 mg per kg / day. Inhaled topical steroids are allowed. * Administration of any immunoglobulin, any immunotherapy or administration of some blood products in the 3 months preceding the study, or planned during the study period. * Any health condition or patient history, in the opinion of the investigator, could interfere with the evaluation of the study's objectives. * Participation in another experimental protocol during the period of the study. * Demonstration, confirmation or suspicion of a condition of immunosuppression or immunodeficiency (including HIV infection) based on medical history and physical examination (no laboratory test). * A family history of congenital or hereditary immunodeficiency. * Subjects taking any of the following medications: antihistamines in the week preceding the consultation, systemic steroids (inhaled or nasal steroids are allowed), anti-cytokines or cytokines, systemic interferon (injection local interferon α for the treatment of HPV is allowed) or treated with systemic chemotherapy.